ProCE Banner Activity

JAK Inhibitors in Rheumatoid Arthritis: Weighing the Anticipated Options

Clinical Thought
Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.

Released: September 09, 2016

Expiration: September 08, 2017

No longer available for credit.

Share

Faculty

Roy Fleischmann

Roy Fleischmann, MD

Clinical Professor of Medicine
Department of Medicine
University of Texas Southwestern Medical Center
Co-Director
Metroplex Clinical Research Center
Partner
Rheumatology Associates
Dallas, Texas

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly USA

Faculty Disclosure

Primary Author

Roy Fleischmann, MD

Clinical Professor of Medicine
Department of Medicine
University of Texas Southwestern Medical Center
Co-Director
Metroplex Clinical Research Center
Partner
Rheumatology Associates
Dallas, Texas

Roy Fleischmann, MD, has disclosed that he has received consulting fees, fees for non-CME services, and funds for research support from AbbVie, Eli Lilly, and Pfizer.